Feature Channels:

Article ID: 719072

A nationally recognized Rutgers cardiologist recommends that aspirin be used as primary prevention for cardiovascular disease only with select patients, saying that the scientific evidence is too diverse to support a one-size-fits-all approach.

Article ID: 718957

Research by the Weizmann Institute of Science's Prof. Yardena Samuels shows that heterogeneity in melanoma tumors prevents effective immune responses

Article ID: 717884

Finding May Create Opportunity to Test Patients to Avoid Ineffective Drugs

Article ID: 717865

A personalized approach to cancer treatment has become more common over the last several decades, with numerous targeted drugs approved to treat particular tumor types with specific mutations or patterns. However, this same personalized strategy has not translated to radiation therapy, and a one-size-fits-all approach for most patients is still common practice. Moffitt Cancer Center researchers hope to change this mindset for radiation treatment with the development of a genomically-based model that can optimize and personalize a radiation dose to match an individual patient’s needs.

Article ID: 717247

The multiple sclerosis drug teriflunomide, paired with targeted cancer therapy, markedly shrinks patient-derived glioblastomas grown in mice by reaching stem cells at the tumor’s root, according to a new UC San Diego School of Medicine study published in Science Translational Medicine.

Article ID: 716114

On August 4, a special session at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo will shed much-needed light on the nuances of direct-to-consumer genetic testing.

Article ID: 716595

Building on a track record of developing adeno-associated viral (AAV) vectors as a groundbreaking clinical tool for gene therapy and gene editing, Children’s Hospital of Philadelphia (CHOP) researchers report a more sensitive method for capturing the footprint of AAV vectors—a broad range of sites where the vectors transfer genetic material.

Article ID: 716429

High blood pressure among children is on the rise and a lack of research about how to treat it has left pediatricians trying to make their best guess. That’s until researchers released results of a pioneering study that used a series of personalized trials to identify a preferred therapy for kids – the first step in tackling the problem.

Article ID: 716359

Imagine that you have a serious medical condition. Then imagine that when you visit a team of doctors, they could build an identical virtual ‘twin’ of the condition and simulate millions of ways to treat it until they develop an effective treatment. That is the vision of a team of scientists, led by Argonne National Laboratory.

Article ID: 716062

Using an ultra-sensitive and high-throughput isolation technology, UCLA researchers were able to characterize and identify the neoantigens driving the antitumor responses in a patient treated with anti-PD-1 blockade and isolate the T cell receptors responsible for such effect.